StreetInsider.com News Articles

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Thu, 19 Feb 2026 07:00:00 -0500

BETHESDA, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s management team will participate in a fireside chat and one-on-one meetings at the Oppenheimer 36^th Annual Healthcare Life Sciences Conference, being held Wednesday, February 25^th through Thursday, February 26^th.

Fireside Chat Details

Date: Wednesday, February 25, 2026

Time: 1:20 p.m. ET

To access a replay of the fireside chat visit here

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Thu, 19 Feb 2026 07:00:00 -0500

Fireside Chat Details

Date: Wednesday, February 25, 2026

Time: 1:20 p.m. ET

To access a replay of the fireside chat visit here

Form 8-K Gain Therapeutics, Inc. For: Feb 03

Tue, 03 Feb 2026 16:25:00 -0500

si-local-file:///var/storage/secattach/20260203/25939265.html

Form 8-K Gain Therapeutics, Inc. For: Feb 03

Tue, 03 Feb 2026 16:25:00 -0500

si-local-file:///var/storage/secattach/20260203/25939265.html

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Wed, 07 Jan 2026 07:00:00 -0500

BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced its attendance at conferences during the week of the 44^th Annual J.P. Morgan Healthcare Conference (“JPM week”) including at the Sachs Neuroscience Innovation Forum, the Demy-Colton/Informa Biotech Showcase™, and the LifeSci Advisors Corporate Access Event.

Information on all events is below.

The 9^th Annual Sachs Neuroscience Innovation Forum
Date: January 11, 2026
Format: Presentation and one-on-one meetings with management.
Presentation

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Wed, 07 Jan 2026 07:00:00 -0500

Information on all events is below.

The 9^th Annual Sachs Neuroscience Innovation Forum
Date: January 11, 2026
Format: Presentation and one-on-one meetings with management.
Presentation

Gain Therapeutics reports biomarker data from Parkinson's trial

Tue, 06 Jan 2026 07:00:49 -0500

Gain Therapeutics Inc. (NASDAQ: GANX) reported biomarker and clinical data from its Phase 1b study of GT-02287 in Parkinson's disease patients, according to a company statement.

The study showed that participants with elevated baseline levels of glucosylsphingosine in cerebrospinal fluid experienced an average 81% decrease after 90 days of treatment with GT-02287. The company stated this represents the first observed reduction in glucosylsphingosine following administration of a GCase modulator to Parkinson's patients.

As of November 30, 2025, 19 patients completed the initial 90-day dosing period. Four patients were excluded from the Movement Disorder Society Unified Parkinson's Disease Rating Scale analysis—two tested negative

Gain Therapeutics reports biomarker data from Parkinson's trial

Tue, 06 Jan 2026 07:00:49 -0500

Gain Therapeutics Inc. (NASDAQ: GANX) reported biomarker and clinical data from its Phase 1b study of GT-02287 in Parkinson's disease patients, according to a company statement.

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

Tue, 06 Jan 2026 07:00:00 -0500

Results to be discussed in KOL event today at 10 a.m. ET

BETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided additional biomarker and clinical data from the Phase 1b clinical study of GT-02287 in people with Parkinson’s disease (PD) with or without a GBA1 mutation that further supports the disease-modifying potential of GT-02287.

In participants with elevated baseline levels of glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF) at baseline, GluSph

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

Tue, 06 Jan 2026 07:00:00 -0500

Results to be discussed in KOL event today at 10 a.m. ET

In participants with elevated baseline levels of glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF) at baseline, GluSph

Gain Therapeutics (GANX) PT Raised to $10 at Roth/MKM

Mon, 22 Dec 2025 08:53:06 -0500

(Updated - December 22, 2025 8:53 AM EST)

Roth/MKM analyst Boobalan Pachaiyappan raised the price target on Gain Therapeutics (NASDAQ: GANX) to $10.00 (from $6.00) while maintaining a Buy rating.

The analyst commented: "In Phase 1b, GT-02287 demonstrated blood-brain barrier penetration and triggered a reduction in GluSph levels, which in our view, provides direct mechanistic evidence for GCase target engagement. A detailed data presentation is expected in the upcoming January 6 KOL event. In light of these findings, we are increasing our 12-month price target to $10 per share from the prior $6 per share."

Gain Therapeutics (GANX) PT Raised to $10 at Roth/MKM

Mon, 22 Dec 2025 08:53:06 -0500

(Updated - December 22, 2025 8:53 AM EST)

Roth/MKM analyst Boobalan Pachaiyappan raised the price target on Gain Therapeutics (NASDAQ: GANX) to $10.00 (from $6.00) while maintaining a Buy rating.

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

Thu, 18 Dec 2025 16:05:00 -0500

Event to be held January 6th, 2026, at 10 a.m. EST

BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it will host a virtual key opinion leader (KOL) event, “Understanding GCase Substrates in Parkinson’s Disease: Perspectives on Biomarkers and Disease Modification, Contextualizing emerging biomarker data from the Phase 1b clinical study of GT-02287”. Featured Key Opinion Leaders (KOLs) will be Roy Alcalay, M.D., M.Sc., Chief of Movement Disorders Division, Tel

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

Thu, 18 Dec 2025 16:05:00 -0500

Event to be held January 6th, 2026, at 10 a.m. EST

Form 8-K Gain Therapeutics, Inc. For: Dec 18

Thu, 18 Dec 2025 09:01:00 -0500

si-local-file:///var/storage/secattach/20251218/25757069.html

Form 8-K Gain Therapeutics, Inc. For: Dec 18

Thu, 18 Dec 2025 09:01:00 -0500

si-local-file:///var/storage/secattach/20251218/25757069.html

Gain Therapeutics reports brain target engagement in Parkinson's study

Thu, 18 Dec 2025 07:00:28 -0500

Gain Therapeutics Inc. (NASDAQ: GANX) announced that its Phase 1b clinical study of GT-02287 showed a reduction in glucosylsphingosine (GluSph) levels in cerebrospinal fluid among Parkinson's disease patients, according to a company statement.

The reduction in GluSph, a substrate of the glucocerebrosidase (GCase) enzyme, was observed in all participants with elevated baseline levels after 90 days of treatment. The company stated this represents the first reported reduction of this biomarker in Parkinson's patients following administration of a GCase modulator.

The Phase 1b study enrolled 21 participants, with 19 completing the 90-day dosing period. Of those, 15 participants chose to continue in a

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease

Thu, 18 Dec 2025 07:00:00 -0500

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint

The reduction in GluSph in CSF, a first-ever observation following the administration of a GCase modulator to PD patients, suggests increased GCase activity in the brain, which is expected to impact the progression of Parkinson’s disease (PD)

KOL event planned for early January to discuss the results; registration information herein

BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease

Thu, 18 Dec 2025 07:00:00 -0500

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint

KOL event planned for early January to discuss the results; registration information herein

BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the

Form S-8 Gain Therapeutics, Inc.

Wed, 03 Dec 2025 16:02:00 -0500

si-local-file:///var/storage/secattach/20251203/25695298.html

Form S-8 Gain Therapeutics, Inc.

Wed, 03 Dec 2025 16:02:00 -0500

si-local-file:///var/storage/secattach/20251203/25695298.html

H.C. Wainwright Reiterates Buy Rating on Gain Therapeutics (GANX)

Mon, 01 Dec 2025 06:36:07 -0500

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $8.00 price target on Gain Therapeutics (NASDAQ: GANX).

The analyst commented: 'We remind investors that additional 90-day data from the GT-02287 Phase 1b trial in Parkinson's disease (PD) patients with or without GBA1 mutations may be released imminently. From our vantage point, these results could inform a more complete picture of the clinical activity profile of the compound. We are expecting both functional outcomes data—specifically, impact on domains of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)—as well as the compound's influence on specific biomarkers, including glucocerebrosidase (GCase) activity

Form 8-K Gain Therapeutics, Inc. For: Nov 28

Fri, 28 Nov 2025 16:03:00 -0500

si-local-file:///var/storage/secattach/20251128/25676769.html

Form 8-K Gain Therapeutics, Inc. For: Nov 28

Fri, 28 Nov 2025 16:03:00 -0500

si-local-file:///var/storage/secattach/20251128/25676769.html

Form 424B5 Gain Therapeutics, Inc.

Fri, 28 Nov 2025 16:02:00 -0500

si-local-file:///var/storage/secattach/20251128/25676732.html